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Context and Significance {#sec1}
========================

**The inability of immune cells to access nutrients or engage particular metabolic pathways can lead to altered functional output. Since inappropriate immune function can cause disease, there is a lot of interest in understanding how immune cell metabolic programming controls cell function. Max Planck researchers investigated the metabolism of regulatory T cells (Tregs), cells that prevent autoimmunity but also suppress anti-cancer immunity. They found that changes to the mitochondria as a consequence of altered lipid metabolism led to greater suppressive capacity, a phenotype also evident in tumor Tregs. These findings highlight a link between mitochondria and lipid metabolism in controlling Treg function and suggest that understanding this pathway may hold promise for the future treatment of autoimmune diseases or cancer.**

Introduction {#sec2}
============

Tregs are responsible for modulating the immune system, maintaining tolerance to self-antigens, and preventing autoimmune disease ([@bib62]). Tregs are defined by the lineage-specifying transcription factor Foxp3, and its expression is essential for their differentiation and suppressor function ([@bib19]). Through a variety of mechanisms, Tregs can inhibit effector T cell proliferation and cytokine production and thereby play a vital role in limiting immune-mediated inflammation ([@bib62]). While the mechanisms of suppression remain to be fully defined, they include the production of soluble mediators, involving cytokines such as IL-10 and TGF-β, that dampen effector T cell proliferation ([@bib12], [@bib32], [@bib61]). While Tregs protect the host by limiting exacerbated immune responses, they can also have a negative impact on host survival in settings such as cancer, where their immunosuppressive function limits effector T cell responses against tumor cells and allows tumor growth ([@bib11], [@bib77]).

The link between cellular metabolism and functional output is well established in the immune system, where aberrant engagement of metabolic pathways in a variety of immune cell subsets can lead to abnormal cell function and disease progression ([@bib43], [@bib49]). Tregs have been shown to rely on lipid metabolism for survival and function ([@bib22], [@bib38]) and, more specifically, to acquire and utilize extracellular free fatty acids to meet their metabolic demands ([@bib7]). Mechanistically, raptor-mTORC1 signals in Tregs augment lipid and cholesterol metabolism to allow cell proliferation and surface expression of important molecules mediating immune suppression such as CTLA-4 and ICOS ([@bib81]). Tregs in tumors have been shown to rely on a combination of glycolysis and fatty acid synthesis and oxidation, allowing their survival and proliferation in the hostile tumor environment ([@bib46]). Together, these data highlight the important role of lipid metabolism in Tregs; however, a complete understanding of how lipids regulate Treg development and function is lacking ([@bib42]).

Within cells, lipids are bound to lipid chaperones, such as fatty acid binding proteins (FABPs) ([@bib20], [@bib71]). FABPs are a family of 14-15 kDa proteins that coordinate lipid trafficking and responses within cells by reversibly binding hydrophobic ligands, such as saturated and unsaturated fatty acids ([@bib20]). FABPs play important roles in fatty acid uptake from the microenvironment, trafficking lipids to specific cellular compartments, including the nucleus, peroxisomes, endoplasmic reticulum (ER), and mitochondria ([@bib20], [@bib31], [@bib70]).

FABP5 is one of the most highly expressed FABPs in T cells ([@bib59]). FABP5 inhibition has been shown to minimize IL-17 cytokine production and skew T cells toward a Treg phenotype *in vitro*, and consistent with this, FABP5 inhibition *in vivo* has been reported to attenuate EAE ([@bib57]). FABP5 has also been shown to be important for tissue-resident memory T cells ([@bib47]) and macrophages ([@bib39], [@bib84]), but mechanistically FABP function is not clearly understood. Given the reported importance of increased lipid metabolism, including increased FAO in Treg cell function ([@bib38]), we set out to examine whether FABP5 plays a pivotal role in these processes.

Results {#sec3}
=======

FABP5 Blockade Inhibits *In Vitro* Treg Proliferation and Mitochondrial Metabolism {#sec3.1}
----------------------------------------------------------------------------------

We examined FABP5 expression in Tregs generated from naive CD4^+^ T cells *in vitro*. FABP5 was more highly expressed in Tregs compared to naive CD4^+^ T cells ([Figure 1](#fig1){ref-type="fig"}A). The expression of *Fabp3*, *Fabp4*, and *Fabp5* was also assessed in *in vitro*-differentiated Th1, Th2, Th17, and Tregs ([Figure S1](#mmc1){ref-type="supplementary-material"}A). *Fabp3* expression was comparable across all Th cell subsets, *Fabp4* expression was highest in *in vitro*-induced Th17 cells, and *Fabp5* was highest in *in vitro*-induced Tregs. *Fabp3* and *Fabp5* were more highly expressed in Th1 and Th17 cells compared to naive CD4^+^ T cells, and *Fabp5* was most highly expressed in Th2 and Tregs compared to naive CD4^+^ T cells ([Figure S1](#mmc1){ref-type="supplementary-material"}B). We next labeled naive CD4^+^ T cells with cell trace violet and cultured them under Treg polarizing conditions in the presence or absence of the FABP inhibitor BMS309403, which targets the fatty acid binding pockets of FABP3, FABP4, and FABP5 ([@bib21], [@bib72]). Both cellular proliferation and Foxp3 expression were inhibited by BMS309403, suggesting a role for FABP5 in Treg differentiation ([Figure 1](#fig1){ref-type="fig"}B). As a control, we also replicated this experiment using Th2 cells, as they also expressed *Fabp5* at higher levels. No difference was evident in the induction of Gata3 in Th2 cells cultured in the presence of BMS309403 versus vehicle control; however, as in Tregs, cellular proliferation was inhibited ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Further, no increase in LDH in the media supernatant was observed following FABP5 inhibition, suggesting that the decreased cellularity was a consequence of impeded proliferation as opposed to cytotoxicity ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Because chronic administration of BMS309403 retarded Foxp3 expression and limited cellular proliferation in this *in vitro*-induced Treg system, we sought to assess the effects of acutely inhibiting FABP5 in fully differentiated Tregs. Using this approach, we were able to circumvent the confounding effects of chronic BMS309403 exposure on Treg differentiation and proliferation and to explore the role of FABP5 in Treg function. Here, we differentiated Tregs *in vitro* for 3 days before incubating the cells with BMS309403 overnight. In this setting, there was a reduction in cell number, but cell viability and Foxp3 expression were preserved ([Figure 1](#fig1){ref-type="fig"}C). We next assessed cellular bioenergetics and found that after BMS309403 treatment, Tregs exhibited decreased basal oxygen consumption rates (OCR), OCR/ECAR (extracellular acidification rate) ratio, and maximal respiratory capacity (evident after exposure to the uncoupler FCCP) ([Figure 1](#fig1){ref-type="fig"}D), indicating decreased mitochondrial activity. Accordingly, basal ECAR was increased when cells were treated with BMS309403, indicating a switch from oxidative phosphorylation to glycolysis after exposure to this inhibitor ([Figure 1](#fig1){ref-type="fig"}D). To extend these findings beyond mouse Tregs, we differentiated human Tregs *in vitro* before acute treatment with BMS309403. Consistent with the mouse Tregs, we also observed decreased OCR and enhanced ECAR ([Figure 1](#fig1){ref-type="fig"}E). Finally, we also tested whether the metabolic effects evident after FABP5 inhibition were reversible. When cells that had been cultured overnight with BMS309403 were washed and allowed to recover for a further 24 h in the absence of the inhibitor, the OCR and ECAR of the cells reverted to the levels measured in Tregs that had not been treated with the inhibitor. Conversely, maintaining cells in the presence of BMS309403 limited cellular bioenergetics ([Figure S2](#mmc1){ref-type="supplementary-material"}A).Figure 1Tregs Express FABP5 during *In Vitro* Differentiation, and Blockade Affects Differentiation and MetabolismNaive CD4^+^ T cells were cultured for 4 days under Treg cell-differentiation conditions.(A) Mean relative expression (±SEM) of *Fabp5* mRNA in *in vitro*-differentiated Tregs compared to naive CD4^+^ T cells (n = 3). FABP5 protein expression was assessed on D4. Results represent two independent experiments.(B) Representative flow plots and quantification of Foxp3 expression and CTV dilution (±SEM) in Tregs cultured in the presence or absence of the FABP5 inhibitor BMS309403 (n = 4). Results represent three independent experiments. Gating controls are depicted in red.(C) Naive CD4^+^ T cells were cultured for 3 days under Treg differentiation conditions before overnight BMS309403 treatment, and mean viability, relative cell number, and Foxp3 expression (±SEM) were measured (n = 4). Results represent \>6 independent experiments. Gating controls are depicted in red.(D--F) Mean (±SEM) basal OCR, basal ECAR, OCR/ECAR ratio and maximal respiration (after FCCP) of *in vitro-*differentiated mouse Tregs (n = 5). Results represent \>6 independent experiments. (D) *In vitro-*differentiated human Tregs (n = 6). Results represent three independent experiments (E) or *in vitro-*differentiated mouse Tregs expressing *Fabp5* shRNA (n = 5). Results represent two independent experiments. (F) cultured in the presence or absence of BMS309403 overnight at baseline, and in response to oligomycin (Oligo), FCCP, and rotenone and antimycin A (R + A).(G) qPCR and protein expression of FABP5 following shRNA knockdown. Results represent two independent experiments. ^∗^p \< 0.05, ^∗∗∗^p \< 0.005, ^∗∗∗∗^p \< 0.001. P values were calculated using a two-tailed, unpaired t test.

In contrast to what we observed after acute pharmacologic inhibition with BMS309403, *in vitro*-generated Tregs from mice chronically deficient for FABP4 and FABP5 (*Fabp4/5* dKO mice) had increased basal OCR, decreased basal ECAR, and enhanced maximal respiratory capacity ([Figure S2](#mmc1){ref-type="supplementary-material"}B). These results suggested that either BMS309403 had off-target effects or that compensatory mechanisms allowed Tregs to develop normally in *Fabp4/5* dKO mice by utilizing alternative pathways after *Fabp4/5* germline deletion. Supporting the latter hypothesis, *in vitro*-generated Tregs from *Fabp4/5* dKO mice had increased gene expression of *Fabp3* compared to cells from WT mice ([Figure S2](#mmc1){ref-type="supplementary-material"}C), suggesting the possibility that this protein might be upregulated to compensate for germline deletion of *Fabp4*/*5*. In contrast, WT Treg cells failed to increase *Fabp3* expression in response to acute FABP inhibition ([Figure S2](#mmc1){ref-type="supplementary-material"}D). Nevertheless, to circumvent possible off-target effects of BMS309403, we took a different genetic approach for acute loss of *Fabp5* function in WT T cells by expressing a short hairpin RNA (shRNA) against *Fabp5* to knock down FABP5 expression. Consistent with the results observed after acute pharmacologic inhibition, we observed decreased basal OCR, OCR/ECAR ratio, and maximal respiration, along with increased ECAR, in Tregs expressing *Fabp5* shRNA ([Figure 1](#fig1){ref-type="fig"}F). ShRNA-mediated knockdown of *Fabp5* mRNA and protein was confirmed in these cells ([Figure 1](#fig1){ref-type="fig"}G). Importantly, no significantly increased expression of *Fabp3* or *Fabp4* was observed following shRNA-mediated knockdown of *Fabp5*, ([Figure S2](#mmc1){ref-type="supplementary-material"}D). Thus, acute genetic depletion of FABP5 matched the results observed after treating cells with BMS309403 overnight, suggesting that the acute loss of FABP function in both settings led to the respiratory defects observed in Tregs.

Memory CD8^+^ T cells (Tmem) have been shown to use oxidative metabolism fueled by glucose-derived lipids ([@bib44]), and a recent report has shown the requirement for FABP4/5 in the maintenance of skin resident CD8^+^ Tmem cells, but not in central CD8^+^ Tmem cells ([@bib44], [@bib47]). To explore a role for FABP5 in *in vitro*-generated Tmem cells, we activated CD4^+^ or CD8^+^ T cells *in vitro* in the presence of IL-2 for 3 days before further differentiation in IL-15 for 3 days ([@bib9]). When cells were switched to IL-15, they were also cultured in the presence of BMS309403 or vehicle control for 3 days. In contrast to *in vitro*-generated Tregs, *in vitro*-generated CD4^+^ and CD8^+^ Tmem cells exposed to BMS309403 showed no defect in mitochondrial respiration ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B), and CD8^+^ Tmem cells exhibited comparable cytokine production ([Figure S3](#mmc1){ref-type="supplementary-material"}C), although there was a small reduction in the expression of CD44 and CD62L ([Figure S3](#mmc1){ref-type="supplementary-material"}D). These results are in agreement with published data suggesting that FABP5 may not be critical for non-tissue-resident Tmem cells like central CD8^+^ Tmem cells ([@bib47]), as these cells predominantly generate lipids from glucose rather than acquire extracellular lipids for energy generation ([@bib44]). Furthermore, these data increasingly support that BMS309403 is not generally toxic to lymphocytes and has specific effects on Tregs.

Mitochondrial Disruption after FABP5 Inhibition in Tregs Is a Result of Defective Lipid Metabolism {#sec3.2}
--------------------------------------------------------------------------------------------------

We next sought to determine the nature of the respiratory defects in Tregs after FABP5 inhibition. Both pharmacologic inhibition of FABP5 and acute shRNA knockdown of *Fabp5* resulted in decreased MitoTracker deep red staining, which can indicate reduced mitochondrial mass and/or respiration ([@bib40]) ([Figure 2](#fig2){ref-type="fig"}A). As mitochondria are essential organelles for respiration, further analysis also revealed decreased protein expression of the electron transport chain (ETC) complexes ([Figure 2](#fig2){ref-type="fig"}B), which was consistent with the observed reduction in OXPHOS in Tregs after BMS309403 treatment or acute *Fabp5* shRNA knockdown ([Figures 1](#fig1){ref-type="fig"}D--1F).Figure 2Impaired OXPHOS, Lipid Metabolism, and Loss of Cristae Structure Underlie Mitochondrial Alterations in Tregs Following FABP5 InhibitionNaive CD4^+^ T cells were cultured for 3 days under Treg cell differentiation conditions before overnight BMS309403 treatment or were transduced with lentivirus expressing *Fabp5* shRNA.(A) Representative histogram and mean (±SEM) quantification of MitoTracker deep red dye (n = 4).(B) Protein expression of the electron transport chain (ETC) complexes. Results represent three independent experiments.(C) Fractional contribution of ^13^C-Palmitate-derived carbons to the intracellular palmitate pool in Tregs following acute FABP5 inhibition (n = 4).(D) Fractional contribution of ^13^C-Palmitate-derived carbons to intermediates of the TCA cycle in Tregs following acute FABP5 inhibition (n = 4). Results represent two independent experiments.(E) Schematic of the generation of monounsaturated cardiolipins from acetyl-CoA by the lipid elongation and saturation pathway. Mean (±SEM) expression of genes involved in the lipid metabolism, elongation, and desaturation pathway was assessed by qPCR (n = 4). Results represent two independent experiments.(F) Tregs were differentiated *in vitro* from naive CD4^+^ T cells isolated from PhAM mice for 3 days before overnight BMS309403 treatment. Scale bar, 2 μm. Representative images and quantification of mitochondrial sphericity (n = 4) are shown. Results represent two independent experiments.(G) Electron micrographs of mitochondria and quantification of mitochondrial area and mitochondrial cristae width from Tregs following acute FABP5 blockade (n = 4). Scale bar, 2 μm in the left panels and 500 nm in the right panels. Results represent two independent experiments.(H) Left: mean (±SEM) quantification of total cardiolipin content. Right: cardiolipin species in Tregs following overnight treatment with DMSO or BMS309403 (n = 4).(I) PCR analysis of mitochondrial DNA content (mtDNA/nDNA) in Tregs following overnight treatment with DMSO or BMS309403. Mitochondrial *ND1* or *ND5/6* were normalized to nuclear gene expression of *18 s.* Results represent two independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.005, ^∗∗∗∗^p \< 0.001. P values were calculated using a two-tailed, unpaired t test (A, C, D, F, left panel, and I) or a two-way ANOVA with Bonferroni correction (E and H, right panel).

To assess lipid utilization and subsequent lipid oxidation in mitochondria, we cultured Tregs in the presence or absence of BMS309403 with ^13^C-palmitate and traced carbons into TCA cycle intermediates. Tracing with ^13^C-palmitate showed accumulation of palmitate-derived carbons in intracellular palmitate stores in the presence of BMS309403; however, there was a reduction in the presence of ^13^C-palmitate-derived carbons in TCA cycle intermediates ([Figures 2](#fig2){ref-type="fig"}C and 2D), indicating reduced β-oxidation and alterations in lipid utilization. Cardiolipin is a unique phospholipid found only in the inner mitochondrial membrane that is important for mitochondrial function, bioenergetics, and respiratory supercomplex formation ([@bib48]). Substrates for cardiolipin biosynthesis are generated from intracellular lipid elongation and desaturation ([@bib50]) ([Figure 2](#fig2){ref-type="fig"}E). Given the observed mitochondrial defects, we assessed the fatty acid elongation and desaturation pathway after FABP5 inhibition. Genes encoding elongation and desaturation of fatty acids were decreased following BMS309403 treatment or *Fabp5* shRNA knockdown ([Figure 2](#fig2){ref-type="fig"}E). These results indicated that lipid metabolism was markedly perturbed in Tregs after FABP5 inhibition, and they showed that defects in FABP5 function also affected expression of downstream genes important for lipid processing, suggesting a negative feedback mechanism between lipid metabolism and transcription.

Morphological changes in mitochondria and cristae width correlate with cellular metabolic changes ([@bib8]). Live-cell confocal microscopy of *in vitro*-generated Tregs from photoactivatable mitochondria (PhAM) mice exhibited a diffuse mitochondrial network ([Figure 2](#fig2){ref-type="fig"}F). In contrast, acute BMS309403 treatment resulted in mitochondria with a punctate morphology, measured by a significant increase in mitochondrial sphericity ([Figure 2](#fig2){ref-type="fig"}F), a phenotype found in T cells with decreased respiration and increased aerobic glycolysis ([@bib8]). Electron microscopy of *in vitro*-generated Tregs showed large, elongated mitochondria with tight cristae ([Figure 2](#fig2){ref-type="fig"}G). However, following BMS309403 treatment, mitochondria were smaller with increased cristae width ([Figure 2](#fig2){ref-type="fig"}G), a phenotype consistent with mitochondrial defects ([@bib15]). In keeping with the decreased expression of genes controlling the lipid elongation and desaturation pathway ([Figure 2](#fig2){ref-type="fig"}E), and with the changes in mitochondrial structure ([Figures 2](#fig2){ref-type="fig"}F and 2G) and function ([Figures 1](#fig1){ref-type="fig"}D--1F), we found decreased levels of cardiolipin species in Tregs after BMS309403 treatment ([Figure 2](#fig2){ref-type="fig"}H) but no difference in the ratio of mitochondrial to nuclear DNA (mtDNA/nDNA) ([Figure 2](#fig2){ref-type="fig"}I). Together, these data illustrate that FABP5 has a function in maintaining lipid metabolism for mitochondrial function and integrity in Tregs. In contrast to the effects observed in Tregs, *in vitro*-generated Tmem cells showed no defect in cardiolipin biosynthesis after BMS309403 treatment ([Figures S3](#mmc1){ref-type="supplementary-material"}E and S3F), consistent with our data showing no loss of oxidative metabolism in these cells with BMS309403 ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B) and supporting the notion that they might not require FABP5 to function.

FABP5 Inhibition Increases Treg Suppression {#sec3.3}
-------------------------------------------

The requirement for oxidative phosphorylation for the suppressive function of Tregs has been previously reported ([@bib6], [@bib23], [@bib78]). Therefore, we expected that the decreased mitochondrial function evident in Tregs after FABP5 inhibition would limit their suppressive capacity. However, we were surprised to find that *in vitro*-differentiated Tregs treated with BMS309403 exhibited an increased ability to suppress proliferation of responder CD4^+^ T cells compared to vehicle-treated Tregs ([Figure 3](#fig3){ref-type="fig"}A). Increased suppression was also observed from isolated human peripheral Tregs following *in vitro* expansion and acute treatment with BMS309403 ([Figure 3](#fig3){ref-type="fig"}B).Figure 3FABP5 Inhibition of Fully Differentiated Tregs Increases Suppression and Expression of the Regulatory Cytokine IL-10Treg suppression assays were performed following acute FABP5 blockade.(A) Quantification of the mean suppression (±SEM) of responder effector cells from *in vitro*-differentiated Tregs following overnight BMS309403 treatment (n = 4). Results represent five independent experiments.(B) Quantification of mean suppression (±SEM) from human Tregs following BMS309403 treatment (n = 4). Results represent the combined results from 4 independent donors.(C) Quantification of mean suppression (±SEM) from *ex vivo* Tregs following 30 min BMS309403 treatment (n = 4). Results represent two independent experiments.(D) Representative histograms and mean (±SEM) quantification of CD25 and ICOS expression on Tregs following acute FABP5 blockade (n = 4). Results represent six independent experiments.(E) Representative histograms and mean (±SEM) quantification of CD25 and ICOS expression on Tregs following lentiviral knockdown of *Fabp5.* Results represent two independent experiments.(F) Mean (±SEM) expression of *Il10* gene expression measured by qPCR (n = 4).(G) Mean (±SEM) protein expression of IL-10 in Tregs after overnight BMS309403 treatment (n = 5). Results represent two independent experiments. Gating controls are depicted in red.(H) Mean quantification (±SEM) of suppression from *in vitro*-generated Tregs following overnight BMS309403 treatment in the presence or absence of anti-IL-10 antibody (αIL10) (n = 4). Results represent four independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.005, ^∗∗∗∗^p \< 0.001. P values were calculated using a two-way ANOVA with Bonferroni correction (A, B, C, and H) or a two-tailed, unpaired t test (D, E, F, and G).

The metabolic requirements of both murine and human natural Tregs (nTregs) *in vivo* have been shown to differ in some aspects from *in vitro*-differentiated Tregs due to differences in tonic signals and environmental cues ([@bib55]). Therefore, we isolated nTregs directly from the periphery of naive mice and acutely treated the cells with BMS309403 prior to assessing their suppressive capacity compared to vehicle-treated nTregs. Again, BMS309403-treated *ex vivo* nTregs had an increased ability to suppress proliferation of responder CD4^+^ and CD8^+^ T cells compared to vehicle-treated nTregs ([Figure 3](#fig3){ref-type="fig"}C). *In vitro*-generated Tregs treated with BMS309403, or expressing *Fabp5* shRNA, showed increased expression of CD25 and ICOS, two proteins expressed on highly suppressive Tregs ([Figures 3](#fig3){ref-type="fig"}D and 3E) ([@bib58], [@bib76], [@bib81]). We next measured expression of IL-10, an inhibitory cytokine expressed by Tregs, and found that it was increased after BMS309403 treatment ([Figures 3](#fig3){ref-type="fig"}F and 3G). Finally, we sought to assess whether IL-10 led to the increased suppression observed after BMS309403 treatment ([Figures 3](#fig3){ref-type="fig"}A--3C). Treg-mediated suppression was abolished by the addition of anti-IL-10 antibody (αIL-10) to the suppression assay, indicating that IL-10 was responsible for mediating suppression of responder cells in this assay, with or without FABP5 inhibition ([Figure 3](#fig3){ref-type="fig"}H).

Induction of Type I Interferon Signaling in Tregs after FABP5 Inhibition {#sec3.4}
------------------------------------------------------------------------

To ascertain why FABP5 inhibition led to greater suppressive capacity, we performed RNA-seq analysis on *in vitro*-generated Tregs after acute BMS309403 treatment. Among the top 40 most differentially regulated genes, 20 genes were related to type I interferon (IFN) signaling ([Figure 4](#fig4){ref-type="fig"}A). Furthermore, ingenuity pathway analysis (IPA) revealed pattern recognition of bacteria and viruses, and activation of IRF by cytosolic pattern recognition receptors, as the top differentially regulated pathways ([Figure 4](#fig4){ref-type="fig"}B). Type I IFNs have been implicated in the stability and function of Tregs under stress conditions, and they have been shown to induce IL-10 gene expression to enhance Treg suppression within the tumor microenvironment ([@bib74], [@bib83]). Confirming the increased expression of genes related to the type I IFN signaling pathway (*Mx1, Ifi44, Rsad2, Ifit3b, Isg15, Cxcl11, Oas2, Mx2, Oasl1, Oas1a, Usp18, Atf3, Ifna4, Ifi204, Ifit3, Cxcl10, Lmna, Il23a, Ddx60, Oasl2*), we observed increased phosphorylation of STAT1~Tyr701~ (pSTAT1~Tyr701~), indicating enhanced type I IFN signaling after BMS309403 treatment or shRNA knockdown of *Fabp5* ([Figure 4](#fig4){ref-type="fig"}C).Figure 4Disrupting FABP5 in Tregs Triggers mtDNA Release and Consequent cGAS-STING-Dependent Type I IFN Signaling, Which Induces Heightened IL-10 ExpressionNaive CD4^+^ T cells were cultured for 3 days under Treg cell-differentiation conditions before overnight BMS309403 treatment.(A) Heatmap of the top 40 differentially regulated genes identified by RNA-seq.(B) Ingenuity pathway analysis of the top regulated pathways in Tregs after acute BMS309403 treatment.(C) Protein expression of pSTAT1~Tyr701~ in Tregs after FABP5 inhibition or *Fabp5* shRNA. Results represent two independent experiments.(D) Representative confocal photomicrograph of mitochondrial staining and DNA in Tregs after overnight BMS309403 treatment. Scale bar, 2 μm.(E) Mean quantification (±SEM) of extra-nuclear and extra-mitochondrial nucleoid structures (n = 4). Results represent two independent experiments.(F) Quantification of cytosolic mtDNA content of Tregs after BMS309403 treatment (n = 3). Results represent two independent experiments.(G) Mean (±SEM) expression of type I IFN-related genes in Tregs after BMS309403 treatment with siRNA-mediated silencing of *cGAS* or *STING* measured by qPCR (n = 4). Results represent two independent experiments.(H) Mean (±SEM) expression of *Il10* gene expression measured by qPCR (n = 4) in Tregs following overnight IFNα exposure (n = 4). Results represent two independent experiments.(I) Mean (±SEM) expression of *Il10* gene expression measured by qPCR (n = 4) in IFNAR KO Tregs after overnight BMS309403 treatment (n = 4). Results represent two independent experiments.(J) Quantification of mean suppression (±SEM) from *in vitro*-differentiated IFNAR KO Tregs following overnight BMS309403 treatment (n = 4). Results represent three independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.005, ^∗∗∗∗^p \< 0.001. P values were calculated using a two-tailed, unpaired t test (E and H) or two-way ANOVA with Bonferroni correction (F, G, I, and J). Statistics shown in (G) are relative to the FABPi group.

Perturbations in mitochondrial integrity have been shown to drive type I IFN signaling via release of mtDNA into the cytosol ([@bib79]). In accordance with the decreased mitochondrial respiration and loss of cristae integrity observed ([Figures 1](#fig1){ref-type="fig"}D--1F, [2](#fig2){ref-type="fig"}A, and 2G), we sought to determine whether mtDNA signaled to promote a type I IFN response after FABP5 inhibition in Tregs. We performed confocal microscopy on *in vitro*-generated Tregs after BMS309403 treatment. Confirming the data from Tregs expressing PhAM ([Figure 2](#fig2){ref-type="fig"}F), Tregs stained with MitoTracker deep red showed a more punctate mitochondrial morphology after BMS309403 treatment as compared to vehicle-treated cells ([Figure 4](#fig4){ref-type="fig"}D). In addition, we observed extra-nuclear and extra-mitochondrial DNA nucleoids throughout the cytoplasm of Tregs after BMS309403 treatment ([Figures 4](#fig4){ref-type="fig"}D and 4E). We performed cytosolic fractionation and recovered DNA from the cytosol of Tregs after BMS309403 treatment and assessed mtDNA by qPCR. We found increased *mtCytB*, *mtND1,* and *mtND4* in BMS309403-treated Treg cytosol ([Figure 4](#fig4){ref-type="fig"}F) compared to vehicle-treated Tregs, suggesting that mtDNA was released into the cytosol after FABP5 inhibition and that this led to the induction of type I IFNs and subsequent type I IFN-regulated gene expression.

The cGAS-STING pathway acts as an important sensor of cytosolic DNA in response to viruses and has also been implicated in the sensing of mtDNA in fibroblasts ([@bib79]). To test whether cytosolic sensing of mtDNA induced the type I IFN response after BMS309403 treatment, we expressed cGAS or STING siRNA in *in vitro*-generated Tregs. In keeping with our results in [Figure 4](#fig4){ref-type="fig"}A, we found that BMS309403 treatment of Tregs resulted in increased expression of *Ifna4* as well as downstream genes associated with type I IFN signaling *Isg15*, *Ifi44*, and *Rsad2*; however, the expression of these genes was reduced to basal levels following siRNA knockdown of cGAS or STING ([Figure 4](#fig4){ref-type="fig"}G). These results indicated that cytosolic DNA sensing by cGAS and STING is critical for the type I IFN signaling evident in Tregs after FABP5 inhibition.

We hypothesized that the changes in mitochondrial structure upon FABP5 inhibition could contribute to mtDNA release and the type I IFN response in these cells. Opa1 is an important protein for regulating mitochondrial morphology and cristae structure in T cells, and cells isolated from mice with tissue specific deletions in Opa1 exhibit disorganized cristae and reduced OXPHOS ([@bib8], [@bib15]), much like Tregs after FABP5 inhibition. We isolated CD4^+^ T cells from mice with a T-cell-specific deletion of *Opa1* (Opa1 KO) and differentiated these cells into Tregs *in vitro*. Although Opa1 KO Tregs exhibited decreased basal OCR, a decreased OCR/ECAR ratio, and decreased maximal respiration as compared to WT Tregs ([Figure S4](#mmc1){ref-type="supplementary-material"}A), a bioenergetic profile similar to Tregs after FABP5 inhibition ([Figure 2](#fig2){ref-type="fig"}), there was no increased pSTAT1~Tyr701~ in Opa1 KO Tregs ([Figure S4](#mmc1){ref-type="supplementary-material"}B), nor was there increased cytosolic mtDNA ([Figure S4](#mmc1){ref-type="supplementary-material"}C). These data suggested that although there were profound mitochondrial alterations in these cells, mtDNA did not trigger a type I IFN response in Opa1 KO Tregs in this setting. These observations suggest that even overt changes in cristae morphology in conjunction with respiratory defects per se do not necessarily lead to mtDNA release.

Additionally, we considered that BMS309403 might directly affect the type I IFN receptor (IFNAR) to induce type I IFN signaling or that type I IFN was required to limit Treg metabolism. However, direct exposure of *in vitro*-polarized Tregs to IFNα had no negative effect on metabolism ([Figure S5](#mmc1){ref-type="supplementary-material"}A). In line, similar decreases in oxidative metabolism were observed in both WT and IFNAR KO Tregs after BMS309403 treatment ([Figure S5](#mmc1){ref-type="supplementary-material"}B), supporting the idea that the mitochondrial dysfunction following FABP5 inhibition is the upstream signal required to promote type I IFN signaling and not that type I interferons limit cellular metabolism in this setting.

Type I IFN signaling has been shown to promote the induction of *Il10* gene expression in Tregs *in vivo* ([@bib69]); thus, we sought to determine if exogenous IFNα would recapitulate this phenotype *in vitro*. We found that overnight exposure of *in vitro*-generated Tregs to IFNα induced *Il10* gene expression ([Figure 4](#fig4){ref-type="fig"}H). In contrast to the increased *Il10* gene expression measured in WT Tregs following acute FABP5 inhibition or exogenous IFNα exposure ([Figures 3](#fig3){ref-type="fig"}F and [4](#fig4){ref-type="fig"}H), no increased *Il10* gene expression was measured in IFNAR KO Tregs after BMS309403 treatment ([Figure 4](#fig4){ref-type="fig"}I). Accordingly, IFNAR KO *in vitro*-generated Tregs did not have increased suppressive capacity following BMS309403 treatment ([Figure 4](#fig4){ref-type="fig"}J). Finally, to further support the relationship between FABP5, type I IFN signaling, and IL-10 expression, we isolated nTregs directly from the periphery of naive mice and transduced these cells with shRNA against *Fabp5*. Similar to our results using *in vitro*-generated Tregs, we found that in nTregs, decreased expression of *Fabp5* led to increased expression of *Isg15*, *Rsad2,* and *Il10* after FABP5 knockdown ([Figure S5](#mmc1){ref-type="supplementary-material"}C).

To further support the STING-mediated promotion of type I IFN signals and IL-10 expression independent of FABP5 in this setting, we differentiated Tregs *in vitro* for 3 days before treating cells with the STING agonist DMXAA ([@bib53]) or vehicle control overnight. In agreement with our other data, induction of *Ifna4*, *Ifi44*, *Isg15*, *Rsad2*, and *Il10* gene expression was significantly increased; however, *Fabp5* gene expression remained stable ([Figure S5](#mmc1){ref-type="supplementary-material"}D). We also observed increased protein expression of IL-10 *in vitro* in response to DMXAA administration ([Figure S5](#mmc1){ref-type="supplementary-material"}E).

Our earlier results showed reversion of inhibited oxidative metabolism in Tregs following BMS309403 washout ([Figure S2](#mmc1){ref-type="supplementary-material"}A); thus, we sought to determine if type I IFN signaling was also decreased after withdrawal of this FABP inhibitor. Following BMS309403 washout, type I IFN genes were significantly decreased to near-basal levels, illustrating the link between defective mitochondrial metabolism mediated by FABP5 inhibition and the induction of type I IFN signaling ([Figure S5](#mmc1){ref-type="supplementary-material"}F). Taken together, these results suggest that mitochondrial abnormalities can result in release of mtDNA to drive cGAS-STING signaling that induces autocrine type I IFN signaling to promote IL-10 expression and enhance Treg suppression.

The Tumor Microenvironment Enhances Type I IFN Signaling in Tregs {#sec3.5}
-----------------------------------------------------------------

The tumor microenvironment (TME) can be nutrient sparse, and glucose limitation within this environment has been shown to have negative consequences on T cell effector function ([@bib10], [@bib26]). Given that lipid uptake and metabolism are important in Tregs, we considered that perhaps a scarcity of nutrients in the TME could also impact lipid metabolism in these cells. We sought to assess whether tumor Tregs had evidence of mitochondrial dysfunction and subsequent type I IFN signaling.

A previously published RNA-seq analysis of the Treg phenotype in primary human breast carcinoma showed that type I IFN signaling was one of the most significantly dysregulated pathways in tumor Tregs relative to peripheral blood Tregs or Tregs in normal breast tissue ([@bib52]). We used this published dataset to directly explore the expression of *FABP5, IL10*, *ISG15*, *IFI44*, and *RSAD2*, and we found increased expression of these genes in human tumor Tregs compared to Tregs from the peripheral blood. ([Figure 5](#fig5){ref-type="fig"}A, [@bib52]). To explore these findings in a murine model, we injected mice with E.G7-OVA tumor cells and 14 days later isolated Tregs from both the spleen and solid tumor and analyzed gene expression. In line with the published human study ([@bib52]), we measured increased gene expression of *Fabp5* in tumor infiltrating Tregs as compared to splenic Tregs as well as *Il10* and type I IFN-stimulated genes *Isg15*, *Ifi44,* and *Rsad2* ([Figure 5](#fig5){ref-type="fig"}B). We also observed decreased BODIPY-labeled C~16~ uptake *in vivo* ([Figure 5](#fig5){ref-type="fig"}C) and found Tregs within the TME to have less mitochondrial mass and/or respiration than splenic Tregs ([Figure 5](#fig5){ref-type="fig"}D), observations that would correlate with altered mitochondrial function and lipid metabolism. Furthermore, we measured increased CD25 and ICOS expression (marks of highly suppressive Treg cells) ([Figure 5](#fig5){ref-type="fig"}E), and IL-10 production ([Figure 5](#fig5){ref-type="fig"}F), by tumor Tregs as compared to splenic Tregs, which mirrored our results from *in vitro*-generated Tregs following acute FABP5 inhibition. Finally, confocal microscopy of tumor Tregs revealed extra-mitochondrial DNA nucleoids throughout the cytoplasm and an increase in mitochondrial sphericity as compared to splenic Tregs, similar to the results observed in *in vitro*-differentiated Tregs following BMS309403 treatment ([Figure 5](#fig5){ref-type="fig"}G).Figure 5Tregs in the Tumor Microenvironment Exhibit a Suppressive Phenotype with Mitochondrial Alterations and Type I IFN Signaling(A) Gene expression levels in Tregs isolated from human breast cancer relative to Tregs from healthy donor PBMC generated from previously published data ([@bib52]).(B) Mice were injected with E.G7-OVA, and Tregs were isolated from the tumor or spleen on D14. Mean (±SEM) gene expression of type I IFN-related genes from intratumoral Tregs, normalized to Tregs isolated from the spleen (n = 5), is shown. Results represent two independent experiments.(C) Representative histograms and mean (±SEM) quantification of Treg lipid uptake *in vivo* following labeled C~16~ administration. Results are representative of 5 mice from one experiment.(D) Representative histograms and mean (±SEM) quantification of Mitotracker deep red staining. Results represent two independent experiments.(E) Representative histograms and mean (±SEM) quantification of CD25 and ICOS from Tregs isolated from the spleen or tumor. Results represent two independent experiments.(F) Representative flow plots and mean (±SEM) quantification of IL-10 expression from Tregs isolated from the spleen or tumor. Results represent two independent experiments. Gating controls are depicted in red.(G) Representative confocal photomicrographs of mitochondria and DNA of Tregs isolated from the tumor or spleen and quantification of mitochondrial sphericity. Scale bar, 2 μm. Results represent one experiment.(H) Mice were injected with E.G7-OVA, and serum, spleens, and tumors were excised on D14. The total lipid content of serum or interstitial fluid of the spleen or tumor was quantified by MS. Results are representative of 8 mice from one experiment.(I) Mean (±SEM) quantification of *Fabp5* gene expression and protein expression in Tregs following overnight culture in lipid or glucose depleted media (n = 4).(J) Mean (±SEM) quantification of labeled C~16~ uptake *in vitro* in Tregs following overnight lipid starvation (n = 4) or from nTregs *ex vivo* from the spleen or tumor of mice (n = 5) as per (F). Results represent two independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.005, ^∗∗∗∗^p \< 0.001. P values were calculated using a two-way ANOVA with Bonferroni correction (A and B) or two-tailed, unpaired t test (C, D, E, G, H, I, and J).

The results we observed with *in vitro* Tregs following FABP5 inhibition were similar to our observations in tumor Tregs. Curiously, however, both human and mouse tumor Tregs displayed increased Fabp5 gene expression. Given our results showing that acute loss of function of FABP5 led to mitochondrial defects, we initially expected that these cells would have decreased expression of FABP5. We therefore sought to reconcile these seemingly disparate findings and understand how tumor Tregs could have enhanced *Fabp5* gene expression, but disrupted mitochondria and type I IFN signaling, that would be more indicative of a loss of FABP5 function. We hypothesized that *in vitro*, there is an abundance of lipids in the media; however, these lipids are unable to be utilized efficiently by the cell when FABP5 is inhibited, either pharmacologically or genetically. Within the tumor microenvironment, we hypothesized that although *Fabp5* is even more highly expressed, there may not be sufficient lipids available for the cell to acquire. Both of these scenarios would hypothetically lead to decreased lipid uptake by Tregs. Following this logic, we speculated that lipid availability and acquisition might serve a regulatory role to modulate the expression of genes involved in lipid trafficking, such as *Fabp5*. Therefore, in a tumor, decreased lipid content of the extracellular milieu might act to augment *Fabp5* expression, but a lack of available lipid substrate would still mimic a loss of FABP5 function. To begin to test these ideas, we injected mice with E.G7-OVA and allowed tumors to develop for 14 days before harvesting the serum, spleen, and tumors to quantify the available extracellular lipid content. Spleens and tumors were digested, and lipids were isolated from equal volumes of interstitial fluid. Lipid content was quantified in the serum of all mice and in the interstitial fluid of the spleen and tumor. Comparatively, we found that there was a distinct paucity of lipids within the interstitial fluid of the tumor ([Figure 5](#fig5){ref-type="fig"}H).

To test whether the availability of lipids in the extracellular environment could influence *Fabp5* gene expression, we cultured Tregs *in vitro* for 3 days before harvesting cells and re-culturing the cells overnight in nutrient-replete media, glucose-deficient media, or lipid-depleted media. In the absence of sufficient lipids, *Fabp5* gene and protein expression increased; however, the glucose-deficient media did not elevate FABP5 protein expression ([Figure 5](#fig5){ref-type="fig"}I). To determine if the increased *Fabp5* gene expression had a functional consequence, we re-plated Tregs from nutrient-replete or lipid-depleted media, or *ex vivo* nTregs isolated directly from spleens or tumors, back into complete media and quantified the uptake of BODIPY-labeled C~16~ after 30 min. BODIPY-labeled C~16~ uptake was greatest in cells that had been exposed to a low-lipid environment, either *in vitro* or within the tumor, as compared to control cells ([Figure 5](#fig5){ref-type="fig"}J). Together, these results support the notion that within the tumor microenvironment, a lack of available lipids from the extracellular milieu results in increased *Fabp5* expression in tumor Tregs. Therefore, the lipid-restrictive environment of the tumor leads to mitochondrial perturbations and subsequent type I IFN signaling in Tregs that lead to greater IL-10 production and enhanced suppressive capacity.

Discussion {#sec4}
==========

As hydrophobic molecules, lipids require chaperones to maintain solubility and travel throughout both the body and the cell. We found the lipid chaperone FABP5 to be highly expressed in Tregs. Acute pharmacological inhibition or shRNA knockdown of *Fabp5* resulted in dysregulation of the mitochondrial network, loss of ETC complexes, and decreased mitochondrial OXPHOS, with a consequent switch to glycolysis. The mitochondrial defects after FABP5 inhibition accompanied impaired expression of genes involved in the lipid elongation and desaturation pathway, correlating with decreased synthesis of cardiolipin, a lipid required for maintenance of mitochondrial integrity ([@bib82]) and ETC supercomplex formation ([@bib28]). This mitochondrial dysfunction led to increased Treg suppressive capacity via the induction of type I IFN signaling and enhanced subsequent IL-10 production, which resulted in heightened proliferative suppression of responder cells *in vitro*. While we did not explore the role of FABP5 in promoting nuclear translocation of transcription factors, we propose that the reduction in the expression of lipid elongation and desaturation genes could be a consequence of decreased PPARγ expression, which, although not highlighted in our results, was downregulated in our RNA-seq data following FABP5 inhibition. Of note, *Fabp5* is a direct PPARγ target; thus, a break in this cycle is likely to have far-reaching consequences for the biology of these cells.

Our *in vitro* data showed that inhibiting FABP5 in Tregs augmented their suppressive capacity. At first glance, however, the increased gene expression of *Fabp5 in vivo* in both human and mouse Tregs in the tumor microenvironment seemed inconsistent with these findings. However, our data revealed a paucity of lipids in the tumor compared to splenic microenvironment, suggesting that tumor Tregs may augment FABP5 in response to low-lipid environments. The relative scarcity of nutrients within not only the TME but also other tissue sites, such as the skin or adipose tissue, may also result in the increased expression of nutrient transporters, as cells struggle to meet their metabolic demands. Along these lines, under hypoxic conditions, and within the tumor microenvironment, CD8^+^ T cells have been shown to increase expression of the glucose transporter Glut1 ([@bib16]).

Lipid trafficking to mitochondrial membranes is likely to play an important part in the regulation and maintenance of mitochondrial structure and function ([@bib63]). Damaged mitochondria have been shown to release mtDNA into the cytosol, which activates the cytosolic DNA sensor cGAS and its adaptor STING, resulting in the induction of type I IFNs and subsequent expression of type I IFN-stimulated genes ([@bib73], [@bib79]). Our data show that this process can be precipitated by loss of function of FABP5, either through inhibition, reduced expression, or by a lack of necessary lipid substrates. In these settings, utilizing PhAM reporter mice, or following intracellular staining protocols and confocal microscopy, we observed distinct punctate mitochondria associated with loss of FABP5 function, corroborating our previously published results showing that this mitochondrial shape in T cells correlates with a decrease in OXPHOS and a concomitant induction of aerobic glycolysis ([@bib8]). Type I IFNs are known to have significant effects on Tregs ([@bib51]). Type I IFN signaling has been shown to promote Treg function under stress conditions ([@bib37]), and the accumulation of IL-10 producing Tregs in tumors requires type I IFN signaling ([@bib29], [@bib69]). Further, our results showing increased IL-10 expression following DMXAA administration in Tregs *in vitro* suggest that Treg function should perhaps be further investigated in settings where DMXAA is used as an anti-tumor therapy *in vivo* ([@bib3], [@bib85]). Our findings demonstrate that Treg-intrinsic mitochondrial damage, by inducing type I IFN production, can play a significant role in increased IL-10 production and thereby shape Treg suppressive capacity.

All FABPs bind to and have relatively high affinity for long-chain fatty acids but possess differences in ligand specificity, binding affinity, and binding mechanism ([@bib13]). FABP3 has a high affinity for omega-6 polyunsaturated fatty acids (PUFAs) ([@bib4], [@bib34], [@bib75]), FABP4 has a high affinity for oleate and has been shown to interact directly with hormone-sensitive lipase (HSL) to promote lipolysis of lipid droplets ([@bib67]). Intriguingly, although FABP5 has a high affinity for saturated fatty acids, such as stearate, and monounsaturated fatty acids, such as oleate ([@bib27]), FABP5 also has a similar binding affinity for retinoic acid (RA). Retinoic acid inhibits cell growth by binding to the nuclear RA receptor (RAR), but it also promotes cell growth upon binding to PPARβ/γ ([@bib65]). The ratio of FABP5 to cellular RA binding protein II (CRABPII) determines the intracellular localization of retinoic acid, with a high FABP5-CRABPII ratio leading to RA activation of PPARβ/γ. Conversely, a low FABP5-CRABPII ratio leads to RAR activation ([@bib66]). Expression of the stimulated by retinoic acid 6 (*Stra6*) gene was downregulated in our RNA-seq analysis from Tregs after BMS309403 treatment, suggesting that the limited flux of lipids into the cell may account for reduced cellular proliferation as opposed to activation of the RAR. It is interesting to note that RA promotes Treg induction from both naive CD4^+^ and CD4^+^CD44^+^ T cells ([@bib24], [@bib41]). Thus, the metabolic requirements of Tregs both *in vitro* and *in vivo* are likely to be dynamic and change throughout the course of differentiation and may also be dependent on the site of activation and nutrient microenvironment.

Confocal microscopy revealed punctate mitochondria with perturbed cristae after FABP5 inhibition, results that hinted at a possible role for mitochondrial remodeling in permitting the release of mtDNA into the cytosol. Opa1 is known to be critical for the fusion of the inner mitochondrial membrane, and T cells deficient for Opa1 have been shown to have defective mitochondrial metabolism ([@bib8], [@bib30]). Following *in vitro* differentiation from naive CD4^+^ T cells, Opa1 KO Tregs showed decreased basal and maximal respiration as expected; however, no increased pSTAT1~Tyr701~ was detected, indicating no induction of type I IFN signaling in this setting. Furthermore, no increased cytosolic mtDNA was detected. These results showed that mtDNA release was not associated with the profound mitochondrial defects observed in the Opa1 KO Tregs, indicating that the effects of FABP5 loss of function that allow mtDNA release might be quite subtle. It will be interesting in future experiments to determine if acute inhibition of Opa1 in Tregs, either genetically or pharmacologically, could lead to type I IFN signaling via mtDNA release. Likewise, it may be useful to determine the suppressive capacity of Opa1 KO Tregs as compared to WT Tregs, which could decouple the metabolic phenotype of the Opa1 KO from the functional outcome observed in WT Tregs following FABP5 inhibition. Opa1 overexpression has been shown to ameliorate the phenotype of mice bearing mutations in *Ndufs4* and *Cox15*, two genes critical for the formation of ETC complex I and IV, respectively ([@bib14]). It remains to be investigated whether overexpression of Opa1, or of the mitochondrial outer membrane fusion machinery MFN1 and MFN2, protects Tregs from mitochondrial dysfunction induced following FABP5 inhibition.

Tregs differentiated *in vitro* in the presence of TGF-β demonstrate high oxidative metabolism, and low glycolytic metabolism, with a preference for fatty acid oxidation ([@bib38]). Conversely, *in vivo* thymic-derived Tregs engage glycolysis and glutaminolysis at comparable levels to effector T cells, with high mTORC1 activity, despite high Foxp3 expression ([@bib42]). Exposure of thymic-derived Tregs to TGF-β *in vitro* was shown to switch metabolism from glycolysis and glutaminolysis to OXPHOS ([@bib54]). In addition to its effects on Tregs, TGF-β can promote OXPHOS in podocytes and hepatocellular carcinoma, highlighting a key role for this cytokine in the regulation of metabolism ([@bib1], [@bib68]). Thus, it would be interesting to examine the effects of FABP5 blockade on Tregs generated *in vitro* in the absence of TGF-β. Differentiation of human Tregs *in vitro* can be achieved with suboptimal TCR stimulation, and these cells maintain suppressive capacity. While these cells utilize lipids and FAO to meet their metabolic demands *in vitro*, they are also dependent on the induction of glycolysis to mediate the splicing of Foxp3 isoforms ([@bib17]). Inhibition of mTORC1 with rapamycin can also promote the differentiation of human and murine Tregs *in vitro* in the absence of TGF-β ([@bib5], [@bib45]). Given the different culture methods used to achieve Treg differentiation *in vitro*, it would be informative to assess the expression of FABP5 in these cells across different culture conditions, and the consequence of FABP5 inhibition or knockdown, to further interrogate the role of cytokine and metabolic influences in determining Treg metabolism and function.

Many studies have shown that Tregs require OXPHOS for suppressive capacity ([@bib6], [@bib23], [@bib78]). In our studies, OXPHOS was decreased in Tregs as a result of FABP5 loss of function, but nevertheless, suppressive activity was improved. We found that Tregs had a compensatory increase in glycolysis after FABP5 inhibition, and these cells also had enhanced suppression. In line with these observations, it has been shown that *ex vivo*-isolated human Tregs are highly glycolytic ([@bib55]). Despite the loss of mitochondrial structure and ETC complexes, Tregs were still equally viable for 36 h following FABP5 inhibition, as compared to vehicle-treated cells. This is important, as the initiation of apoptosis has been shown to block mtDNA-induced type I IFN signaling ([@bib60], [@bib80]). This is a critical checkpoint to ensure that cellular apoptosis remains immunologically silent and does not trigger innate immune activation. Although our experiments showing that Tregs cultured in BMS309403 recovered metabolic homeostasis when the drug was washed out, it remains to be seen if Tregs undergo apoptosis following longer-term FABP5 inhibition and whether the induction of type I IFN signaling and subsequent IL-10 production wane over time. We speculate that long-term mitochondrial alterations mediated by this pathway could lead to increased Treg cell death. In this case, our data would align with recent findings that tumor Tregs have greater suppressive capacity linked to inadvertent death due to oxidative stress ([@bib36]). In that study, it was shown that apoptotic Tregs mediated immunosuppression via adenosine rather than IL-10 ([@bib36]). Together, these findings support the view that Tregs possess multiple suppressive mechanisms and, in certain settings, may not always have to be what is considered "optimally" fit to perform suppressor functions ([@bib64]). Our study illuminates a novel link between mitochondrial health and lipid metabolism and how this serves as a Treg-intrinsic checkpoint for the expression of type I IFN/IL-10-mediated suppressive mechanisms.

Limitations of Study {#sec4.1}
--------------------

Future additional work will be aimed at further exploring the metabolism of tumor infiltrating Tregs. However, based on the mitochondrial network shown by confocal microscopy and decreased MitoTracker red staining, we propose that tumor Tregs would have limited capacity for OXPHOS compared to splenic Tregs. Furthermore, this study has not shown the direct expression of type I IFN by Tregs in tumors, but rather, it has shown that they have mitochondrial dysfunction and a type I IFN-stimulated gene signature. More work will have to be done to determine the relevance of Treg cell-derived type I IFN expression during cancer.

STAR★Methods {#sec5}
============
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-------------------
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Lead Contact and Materials Availability {#sec5.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be made available upon reasonable request by the Lead Contact, Erika L. Pearce (<pearce@ie-freiburg.mpg.de>). This study did not generate new unique reagents.

Experimental Model and Subject Details {#sec5.3}
--------------------------------------

### Mouse Models {#sec5.3.1}

C57BL/6J (RRID: IMSR_JAX:000664), PhAM (RRID: IMSR_JAX:018397), IFNAR KO (MMRRC_32045) and TIGER/FIR mice (RRID: IMSR_JAX:008379) and CD45.1 congenic (RRID: IMSR_JAX:002014) mouse strains were purchased from The Jackson Laboratory. Opa1 conditional floxed mice (obtained from Dr. Hiromi Sesaki at Johns Hopkins University School of Medicine, Baltimore, MD) were crossed to CD4-Cre mice (obtained from Dr. Yongwon Choi at the University of Pennsylvania) to generate Opa1flox/flox CD4-Cre mice (maintained on a C57BL/6J background). All mice were maintained at the Max Planck Institute for Immunobiology and Epigenetics or the University of Minnesota and cared for according to the Institutional Animal Use and Care Guidelines.

### Primary Cell culture {#sec5.3.2}

Total CD4^+^ T cells were positively selected by MACS isolation from spleen and peripheral LNs of C57BL/6 mice. Cells were cultured on anti-CD3 coated plates (5 μg/mL) at a density of 1 × 10^6^/mL with 0.5 μg/mL anti-CD28, 100 U/mL IL-2, 5 ng/mL TGF-β and 10 ug/mL anti-IL-4, anti-IL-12 and anti-IFN-γ in 1640 RPMI media supplemented with 10% Hyclone serum, 1% Penstrep and 1% L-Glut and 55 μM beta-mercaptoethanol. After 72 h, cells were split 1:2 either in the presence or absence of BMS309403 (50 μM, solubilized in DMSO) or DMXAA (200 μM, solubilized in DMSO), or vehicle control. In some experiments, cells were cultured in the presence of BMS309403 or DMSO from the start of culture. For washout experiments, cells were harvested on day 4, washed to remove any residual BMS309403 or DMSO and cultured for a further 24 h. Th1 cells were differentiated on anti-CD3 coated plates (5 μg/mL) at a density of 1 × 10^6^/mL with 0.5 μg/mL anti-CD28, 100 U/mL IL-2, 10 ng/mL IL-12 and 10 ug/mL anti-IL-4. Th2 cells were differentiated on anti-CD3 coated plates (5 μg/mL) at a density of 1 × 10^6^/mL with 0.5 μg/mL anti-CD28, 100 U/mL IL-2, 10 ng/mL IL-4 and 10 ug/mL anti-IL-12 and anti-IFN-γ. Th17 cells were differentiated on anti-CD3 coated plates (5 μg/mL) at a density of 1 × 10^6^/mL with 0.5 μg/mL anti-CD28, 10 μg/mL IL-1β, 10 ng/mL IL-6, 5 ng/mL TGF-β and 10 ug/mL anti-IL-4 and anti-IFN-γ.

For human studies, T cells were isolated from buffy coats that were kindly provided by the Institute for Transfusion Medicine and Gene Therapy, Medical Center -- University of Freiburg (donor consent, anonymized) or at the University of Minnesota. Healthy donor blood was diluted 1:1 with PBS and layered over lymphoprep in SepMate PBMC Isolation tubes. Samples were centrifuged at 1200 x g for 15 min and PBMCs were poured off into a new tube. Human CD4^+^ T cells were positively isolated from the PBMC fraction by MACS separation. CD4^+^ T cells were cultured *in vitro* with human CD3/CD28 T cell activator beads (StemCell). 100 U/mL rhIL-2 and 5 ng/mL rhTGF-β for 7 days in 1640 RPMI media supplemented with 10% Hyclone serum, 1% Penstrep and 1% L-Glut and 55 μM beta-mercaptoethanol. After 7 days, human cells were split 1:2 either in the presence or absence of BMS309403 (250 μM, solubilized in DMSO) or vehicle control over night before analysis. Human cells were found to have a higher tolerance for FABP5 inhibition (Murine cells were found to be sensitive to BMS309403 at 50 μM where as human cells required 250 μM for efficacy). For CD4^+^ and CD8^+^ Tmem cell cultures, isolated cells were plated on anti-CD3 coated plates with 0.5 μg/mL anti-CD28 and 100 U/mL rhIL-2 for 3 days before being harvested and re-plated in the presence of rmIL-15 for a further 3 days. All cell culture was performed under 5% CO~2~ atmospheric oxygen, at 37°C in a humidified incubator.

### Cell Lines {#sec5.3.3}

The murine EL4 lymphoblast cell line expressing OVA (E.G7-OVA) was purchased from ATCC (ATCC Cat\# CRL-223). Cells were cultured for two passages before being implanted in the left flank of naive female mice. Further authentication of the cell line was not performed. The sex of the cell line is female. Cells were maintained in 1640 RPMI media supplemented with 10% GIBCO serum, 1% Penstrep and 1% L-Glut and 55 μM beta-mercaptoethanol, under 5% CO~2~ atmospheric oxygen, at 37°C in a humidified incubator.

Method Details {#sec5.4}
--------------

### *In Vivo* Tumor Experiments {#sec5.4.1}

Mice were injected subcutaneously into the left flank with 1 × 10^6^ E.G7-OVA in sterile PBS. After 14 days, mice were sacrificed and spleens and tumors harvested for further phenotyping. For lipid uptake, labeled C~16~ was administered to mice at 50 mg/kg 30 minutes prior to sacrifice.

### qPCR {#sec5.4.2}

RNA was isolated from cell pellets using the QIAGEN easy kit as per the manufacturers instructions. RNA was reverse transcribed to cDNA by AB cDNA synthesis kit as per the manufacturers instructions. qPCR was performed using the iTaq Universal Probes Supermix (Biorad) and Taqman primers (Thermo Fisher Scientific). Fold change was assessed using the 2ˆ-(ddCT) method using 18S as a reference gene.

### RNA Seq {#sec5.4.3}

Total RNA was extracted from cell pellets using the QIAGEN easy kit as per the manufacturer's instructions and quantified using Qubit 2.0 (Thermo Fisher Scientific). Libraries were prepared using the TruSeq stranded mRNA kit (Illumina) and sequenced in a HISeq 3000 (Illumina) by the Deep-Sequencing Facility at the Max Planck Institute for Immunobiology and Epigenetics. Sequenced libraries were processed with the Galaxy platform and deepTools ([@bib2], [@bib56]), using STAR ([@bib18]) for trimming and mapping and featureCounts ([@bib33]) to quantify mapped reads. Raw mapped reads were processed in R (Lucent Techonologies) with DESeq2 ([@bib35]) to determine differentially expressed genes and generate normalized read counts to visualize as heatmaps using Morpheus (Broad Institute). Pathway enrichment analysis was performed using Ingenuity Pathway Analysis (QIAGEN) which makes predictions using pairwise comparisons between conditions, incorporating statistically significant changes in the gene expression within each of the comparisons.

### Total Lipid and Cardiolipin Quantification {#sec5.4.4}

Mouse blood was collected post-euthanasia and allowed to clot at room temp for 1 hour Samples were spun at 10,000 x g for 10 min and serum was isolated. Spleens and tumors were excised and mechanically dissociated in 2.5 mg/mL collagenase I and collagenase II with 5 ug/mL DNase before incubation at 37°C for 1 h. Samples were centrifuged at 500 x g for 4 min to remove solid debris and equal volumes of fluid were taken for lipid isolation and analysis. Lipids were quantified using the MTBE extraction protocol. Briefly, frozen cell pellets were resuspended in 100 μL ice cold PBS and transferred to 8 mL glass tubes before the addition of methanol. Methyl tert-butyl ether was added and tubes were shaken for 1 h at 4°C. Water was added to separate the phases before centrifugation at 1,000 x g for 10 min. The upper organic phase was collected and dried in a Genevac EZ2 speed vac. Samples were resuspended in 2:1:1 isopropanol:acetonitrile:water prior to analysis. LC-MS was carried out using an Agilent Zorbax Eclipse Plus C18 column using an Agilent 1290 Infinity II UHPLC inline with an Agilent 6495 Triple Quad QQQ-MS. Lipids were identified by fragmentation and retention time, and were quantified using Agilent Mass Hunter software. Cardiolipins were quantile normalized using the preprocesscore R package. Serum lipids were normalized to volume while tumor and spleen lipid quantity were normalized to organ weight.

### Metabolic Phenotyping {#sec5.4.5}

Oxygen consumption rate (OCR) and extraellular acidification rate (ECAR) were measured using the Seahorse XFe bioanalyser. 1.5x10^5^ T cells per well (\> 3 wells per sample) were spun onto poly-D-lysine coated seahorse 96 well plates and preincubated in Seahorse XF media (non-buffered RMPI + 10 μM L-glutamine + 10 μM sodium pyruvate + 25 mM glucose) at 37°C for a minimum of 30 min in the absence of CO~2~. OCR and ECAR were measured under basal conditions, and after the addition of the following drugs: 1 μM oligomycin, 1.5 μM flurorcarbonyl cyanide phenylhydrazone (FCCP) and 100 nM rotenone + 1μM antimycin A as indicated. Measurements were taken using a 96 well Extracellular Flux Analyzer (Seahorse bioscience).

### Flow Cytometry {#sec5.4.6}

Fluorochrome-conjugated monoclonal antibodies were purchased form eBioscience or BDBioscience. Staining was performed in PBS containing 2% FBS (GIBCO) + 2mM EDTA (Thermo Fisher), on ice. Dead cells were excluded with the Life/Dead Fixable Blue Cell Stain Kit (Thermo Fisher). For analysis of mitochondrial mass, MitoTracker Deep Red (Thermo Fisher) staining was performed in complete media at 37°C + 5% CO~2~ for 30 min. Lipid uptake was assessed by incubation with 1 μM C~16~-BODIPY (Thermo Fisher) in complete RPMI for 30 min at 37°C + 5% CO~2~. Intracellular staining was performed using the eBioscience Foxp3 staining kit as per manufacturers instructions. Samples were stored in 1% PFA, diluted in flow buffer before acquisition on LSR Fortessa flow cytometers with FACSDiva Software. After exclusion of doublets, and dead cells, Tregs were identified as CD4^+^Foxp3^+^ cells. Appropriate gating and negative controls were used in each experiment to identify cell populations.

### Confocal and Electron Microscopy Imaging {#sec5.4.7}

The analysis of mitochondrial morphology in live cells was performed as described ([@bib8]). Briefly, *in vitro* differentiated Treg cells from PhAM mice were treated as described and imaged live on glass bottom dishes (MAtTek) coated with poly-D-lysine in complete medium using a Zeiss spinning disk confocal with an Evolve (EMCCD) camera. Cells were kept in a humidified incubation chamber at 37°C with 5% CO2 during image collection. Images were deconvolved using Huygens imaging software and analyzed using the surface features of Imaris imaging software.

For the analysis of mtDNA nucleoids, *in vitro* differentiated or *ex vivo* Tregs FACS sorted from tumors or spleens were stained with Mitotracker Deep Red (Invitrogen) for 20 min at 37°C and adhered to coverslips coated with poly-D-lysine (Sigma) in complete medium. After washing in PBS, cells were fixed with 4% formaldehyde for 15 min, permeabilized with 0.05% Triton X-100 in PBS for 5 min and blocked with PBS containing 3% FBS for 30 min. Then, cells were stained with anti-DNA antibody (Progen, clone AC-30-10) for 90 min, stained with appropriate secondary antibody for 60 min (Invitrogen) and stained with Hoechst 42 (Molecular Probes) for 10 min. Cells were washed twice with PBS containing 1.5% FBS between each step. Coverslips were mounted with Prolong Gold anti-fade reagent (Molecular Probes). Approximately 10 fields of view from distinct biological replicates were captured at random with an LSM880 - Airyscan microscope with a Plan-Apochromat 63x 1.4 oil objective. Images were deconvolved using Huygens imaging software and analyzed using the surface and particle features of the Imaris imaging software.

For electron microscopy, 6x10^6^ cells were fixed in 2.5% glutaraldehyde in 100 mM sodium cocodylate, washed in cocodylate buffer. After dehydration samples were embedded in Eponate 12 resin and sections were cut. Images were acquired using a JOEL 1200 EX transmission electron microscope with an ATMP digital camera or a FEI Tecnai 12 Transmission electron microscope equipped with a TIETZ digital camera. Mitochondria size and cristae width was measured using ImageJ software and averaged over 30 independent images.

### Western Blotting {#sec5.4.8}

For western blot analysis, cells were washed with ice cold PBS and lysed in 1 x Cell Signaling lysis buffer (20 mM Tris-HCL \[pH 7.5\], 150 mM NaCl, 1 mM Na~2~EDTA, 1mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1mM Na~3~VO~4~, 1 μg/mL leupeptin), supplemented with 1mM PMSF. Samples were freeze thawed three times followed by centrifugation at 20,000 x g for 10 min at 4°C. Cleared protein lysate was denatured with LDS loading buffer for 10 min at 70°C and loaded onto precast 4% to 12% bis-tris protein gels. Proteins were transferred onto nitrocellulose membranes using the iBLOT2 system following the manufacturers protocols. Membranes were blocked with 5% w/v milk and 0.1% Tween-20 in TBS and incubated with the appropriate antibodies in 5% w/v BSA in TBS with 0.1% Tween-20 overnight at 4°C. All primary antibody incubations were followed by incubation with secondary HRP-conjugated antibody (Pierce) in 5% milk and 0.1% Tween-20 in TBS and visualized using SuperSignal West Pico or Femto Chemiluminescent Substrate (Pierce) on Biomax MR Film (Kodak). Optical density of the signals on the film was quantified using grayscale measurements in ImageJ software (NIH) and converted to fold change, normalized to the loading control.

### shRNA Delivery {#sec5.4.9}

Isolated CD4^+^ T cells were transduced with empty vector (EV) or *Fabp5* shRNA expressing lentivirus by centrifugation for 90 min (1,000 x g) in the presence of polybrene (8 μg/mL) and HEPES (10 mM). Following centrifugation, supernatant was replaced with fresh viral supernatant containing polybrene (8 μg/mL), HEPES (10 mM) and IL-7 10 U/mL and cells were incubated overnight at 37°C + 5% CO~2~.

### siRNA Delivery {#sec5.4.10}

For siRNA transfection, we used the smartpool accell siRNA for murine cGAS (GE Dharmacon Cat\# E-055528-00-0005) or STING (GE Dharmacon Cat\# E-055608-00-0005) according to the manufacturer's recommendations with minor modifications. Briefly isolated CD4^+^ T cells were cultured overnight at 37°C + 5% CO~2~ in Accell delivery medium (Cat\# B-005000) supplemented with 1% fetal calf serum (Hyclone) and IL-7 at 10 U/mL.

### Mouse Treg Suppression Assays {#sec5.4.11}

For assessment of the suppressive function of *in vitro* generated Tregs, cells were treated overnight with 50 μM BMS309403 or left untreated. Cells were harvested and washed to remove any residual BMS309403, before a serial dilution of cells was made. CD4^+^ T cells from CD45.1 congenic mice were labeled with Cell Trace Violet and added to Tregs. BMDCs were added on top of Treg and congenic responders with 0.5 μg/mL anti-CD3. In some experiments, anti-IL-10 was added to a final concentration of 10 μg/mL. For assessment of Tregs *ex vivo*, cells were purified from the spleen and peripheral lymph nodes of C57BL/6 mice using the EasySep CD4^+^ negative selection followed by CD25 positive selection to yield 99.9% CD4^+^CD25^+^ T cells). Following purification, cells were treated with 50 μM BMS309403 for 90 min at 37°C + 5% CO~2~. Conventional T cells and APCs were purified from C57BL/6 congenic mice and labeled with Cell Trace Violet. A serial dilution of Tregs was made before conventional T cells and APCs were added for 72 h. Suppression was calculated as: $100 - \frac{Proliferation\ in\ presence\ of\ Treg}{Proliferation\ in\ absence\ of\ Treg}x100$

### Human Treg Suppression Assay {#sec5.4.12}

Naive thymic derived Tregs were isolated from human PBMCs by CD25 bead enrichment followed by FACS for CD4^+^CD25^2+^CD127^-^CD45RA^+^ naive Tregs. Cells were initially expanded on KT64/86 cells for two weeks before freezing until required ([@bib25]). For the assays shown, tTreg were thawed, re-stimulated with anti-CD3/28 beads, and expanded for 10 days. Prior to the suppression assays, tTregs were harvested and incubated for 30 min with 250 μM BMS309403 at 37°C + 5% CO~2~. Cells were washed before the assay to remove any residual BMS309403. To assess suppression, PBMCs were purified, labeled with CFSE (carboxyfluorescein succinimidly ester) (Invitrogen, Carlsbad, CA), and stimulated with anti-CD3 mAb coated beads (Dynal, Invitrogen, Calrsbad, CA) ± tTreg (1:4 to 1:16 tTregs/PBMCs). On day 4, cells were stained with antibodies to CD4 and CD8 and suppression was determined from the Division Index (FlowJo, Treestar)

Quantification and Statistical Analysis {#sec5.5}
---------------------------------------

Flow cytometry data was analyzed using FlowJo 10 (BD Biosciences). Statistical Analysis was performed using Prism 6 software (GraphPad) and results are represented as Mean ± SEM, unless otherwise indicated. Comparisons for two groups were calculated using unpaired two-tailed Student's t tests. Comparisons of more than two groups were calculated using one-way ANOVA with Bonferroni's multiple comparison tests. Comparisons of grouped data were calculated using two-way ANOVA with Bonferroni's multiple comparisons tests. We observed normal distribution and no difference in variance between groups in individual comparisons. Selection of sample size was based on extensive experience with metabolic assays. The sample size for *in vivo* tumor experiments was based on previous experience with the tumor cell line. The number of independent experiments performed, and the *p* values for each experiment are reported in the corresponding figure legends. For both *in vitro* and *in vivo* experiments, no initial exclusion criteria were used and no animals or replicates were excluded from the study.

Data and Code Availability {#sec5.6}
--------------------------

The RNA sequencing data generated in this study have been deposited in the Gene Expression Omnibus (GEO) repository (accession number: GEO: [GSE126245](ncbi-geo:GSE126245){#intref0045}).
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